IT201700121764A1 - Composition for the treatment and / or prevention of neurodegenerative diseases. - Google Patents

Composition for the treatment and / or prevention of neurodegenerative diseases.

Info

Publication number
IT201700121764A1
IT201700121764A1 IT102017000121764A IT201700121764A IT201700121764A1 IT 201700121764 A1 IT201700121764 A1 IT 201700121764A1 IT 102017000121764 A IT102017000121764 A IT 102017000121764A IT 201700121764 A IT201700121764 A IT 201700121764A IT 201700121764 A1 IT201700121764 A1 IT 201700121764A1
Authority
IT
Italy
Prior art keywords
prevention
treatment
composition
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
IT102017000121764A
Other languages
Italian (it)
Inventor
Maio Umberto Di
Original Assignee
Neilos S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos S R L filed Critical Neilos S R L
Priority to IT102017000121764A priority Critical patent/IT201700121764A1/en
Priority to PCT/IB2018/058366 priority patent/WO2019082136A1/en
Priority to EP18807123.7A priority patent/EP3700631A1/en
Publication of IT201700121764A1 publication Critical patent/IT201700121764A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
IT102017000121764A 2017-10-26 2017-10-26 Composition for the treatment and / or prevention of neurodegenerative diseases. IT201700121764A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT102017000121764A IT201700121764A1 (en) 2017-10-26 2017-10-26 Composition for the treatment and / or prevention of neurodegenerative diseases.
PCT/IB2018/058366 WO2019082136A1 (en) 2017-10-26 2018-10-26 A composition for the treatment and/or prevention of neurodegenerative diseases
EP18807123.7A EP3700631A1 (en) 2017-10-26 2018-10-26 A composition for the treatment and/or prevention of neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000121764A IT201700121764A1 (en) 2017-10-26 2017-10-26 Composition for the treatment and / or prevention of neurodegenerative diseases.

Publications (1)

Publication Number Publication Date
IT201700121764A1 true IT201700121764A1 (en) 2019-04-26

Family

ID=61257033

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000121764A IT201700121764A1 (en) 2017-10-26 2017-10-26 Composition for the treatment and / or prevention of neurodegenerative diseases.

Country Status (3)

Country Link
EP (1) EP3700631A1 (en)
IT (1) IT201700121764A1 (en)
WO (1) WO2019082136A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269863A (en) * 2019-07-24 2019-09-24 江苏秋之友药业有限公司 A kind of compound preparation of citicoline
CN111548401B (en) * 2020-06-04 2022-08-02 中国中医科学院中药研究所 Salvia miltiorrhiza ERF-VII transcription factor SmERF73 and application thereof
CN112999231A (en) * 2021-03-01 2021-06-22 杭州百晓生物技术有限公司 Application of medicine in reducing side effect of anesthetic

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) * 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
WO2007059762A1 (en) * 2005-11-25 2007-05-31 Gisela Susilo Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide
WO2007106049A1 (en) * 2006-03-16 2007-09-20 Moleac Pte Ltd Combination therapy for treatment of patients with neurological disorders and cerebral infarction
US20080213401A1 (en) * 2007-02-07 2008-09-04 Smith Kyl L Nutritional supplements for healthy memory and mental function
CN101439034A (en) * 2007-11-22 2009-05-27 沈阳沃森药物研究所 Tanshinone IIA lipid complexes and micelle composition thereof for injection
US20110064794A1 (en) * 2008-01-16 2011-03-17 Shenyang Pharmaceutical University Drug Delivery System, its Preparation Process and Use
US20110274680A1 (en) * 2009-10-02 2011-11-10 Mazed Mohammad A Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700068608A1 (en) * 2017-06-20 2018-12-20 Neilos S R L Composition for treatment or prevention of a neurodegenerative disease

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) * 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
WO2007059762A1 (en) * 2005-11-25 2007-05-31 Gisela Susilo Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide
WO2007106049A1 (en) * 2006-03-16 2007-09-20 Moleac Pte Ltd Combination therapy for treatment of patients with neurological disorders and cerebral infarction
US20080213401A1 (en) * 2007-02-07 2008-09-04 Smith Kyl L Nutritional supplements for healthy memory and mental function
CN101439034A (en) * 2007-11-22 2009-05-27 沈阳沃森药物研究所 Tanshinone IIA lipid complexes and micelle composition thereof for injection
US20110064794A1 (en) * 2008-01-16 2011-03-17 Shenyang Pharmaceutical University Drug Delivery System, its Preparation Process and Use
US20110274680A1 (en) * 2009-10-02 2011-11-10 Mazed Mohammad A Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline

Also Published As

Publication number Publication date
EP3700631A1 (en) 2020-09-02
WO2019082136A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
DK3600281T3 (en) COMBINATION THERAPY FOR THE TREATMENT OR PREVENTION OF TUMORS
MD3804737T2 (en) Compositions comprising bacterial strains
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
DK3478679T3 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL286767A (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
EP3641545A4 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
IT201700121764A1 (en) Composition for the treatment and / or prevention of neurodegenerative diseases.
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
DK3290051T3 (en) Pharmaceutical composition for the treatment and / or prevention of cancer
IT201700060506A1 (en) Composition for the prevention and / or treatment of diseases associated with inflammation and / or hyperalgesia
IL261779B (en) Compositions for the treatment and prevention of hoof and claw diseases
HK1249044A1 (en) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases
IL274588A (en) Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
IT201700121799A1 (en) Composition for the prevention and / or treatment of neurodegenerative diseases.
EP3838272A4 (en) Composition for prevention or treatment of neurodegenerative disease
ZA201808182B (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
IL259383A (en) Compound for use in the prevention and treatment of neurodegenerative diseases
EP3534924A4 (en) Composition for the prevention and/or treatment of cardiovascular diseases
IT201700048750A1 (en) COMPOSITION FOR THE TREATMENT OF AFTE AND BUCCALE ULCERS
ITUA20163037A1 (en) Formulations for use in the treatment or prevention of urological disorders
IT201600109507A1 (en) COMPOSITION FOR THE PREVENTIVE OR CURATIVE TREATMENT OF LIVER DISORDERS
IT201700083444A1 (en) Composition for the prevention and / or treatment of thyroid diseases